Literature DB >> 7260980

Alterations in regional myocardial distribution and arrhythmogenic effects of aprindine produced by coronary artery occlusion in the dog.

S Nattel, D H Pedersen, D P Zipes.   

Abstract

Little information exists regarding the effects of coronary artery occlusion on the distribution and actions of antiarrhythmic agents. We administered aprindine to dogs before, 5 min after, and 24 h after one-stage left anterior descending coronary artery (LAD) occlusion. Coronary artery occlusion performed after aprindine administration slowed the rate of disappearance of aprindine from the ischaemic zone compared with the normal zone, so that ischaemic zone aprindine concentrations averaged more than twice normal zone aprindine concentrations 1 h after LAD occlusion. When LAD occlusion was performed before aprindine administration, ischaemic zone aprindine concentrations were initially less than 15% of normal zone aprindine concentrations and increased with time to approach half of normal zone aprindine concentrations 70 min after LAD occlusion. Seventeen of 35 dogs (49%) receiving aprindine before LAD occlusion experienced sustained ventricular tachycardia or ventricular fibrillation, compared with 5/34 (14%) receiving aprindine immediately after LAD occlusion (P less than 0.01), 1/10 (10%) undergoing LAD occlusion without receiving aprindine (P less than 0.05) and 0/16 receiving aprindine without LAD occlusion (P less than 0.01). Aprindine administered 24 h after CO reduced premature ventricular complexes from a mean of 35 to 12 per 100 beats (P less than 0.01) occlusion importantly modifies the regional myocardial distribution of aprindine and its effects on ventricular arrhythmias after coronary artery occlusion.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7260980     DOI: 10.1093/cvr/15.2.80

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  11 in total

Review 1.  Antiarrhythmic drug classifications. A critical appraisal of their history, present status, and clinical relevance.

Authors:  S Nattel
Journal:  Drugs       Date:  1991-05       Impact factor: 9.546

2.  The Treatment of PVCs and Prevention of Sudden Cardiac Death: New findings from the CAST study.

Authors:  S Nattel
Journal:  Can Fam Physician       Date:  1991-01       Impact factor: 3.275

Review 3.  Is there a future for antiarrhythmic drug therapy?

Authors:  P G Guerra; M Talajic; D Roy; M Dubuc; B Thibault; S Nattel
Journal:  Drugs       Date:  1998-11       Impact factor: 9.546

4.  Arrhythmia susceptibility and myocardial composition in diabetes. Influence of physical conditioning.

Authors:  S Bakth; J Arena; W Lee; R Torres; B Haider; B C Patel; M M Lyons; T J Regan
Journal:  J Clin Invest       Date:  1986-02       Impact factor: 14.808

5.  Interaction of ischaemia and encainide/flecainide treatment: a proposed mechanism for the increased mortality in CAST I.

Authors:  H M Greenberg; E M Dwyer; J S Hochman; J S Steinberg; D S Echt; R W Peters
Journal:  Br Heart J       Date:  1995-12

Review 6.  Antiarrhythmic drug treatment: need for continuous vigilance.

Authors:  H J Wellens; J L Smeets; M Vos; A P Gorgels
Journal:  Br Heart J       Date:  1992-01

Review 7.  The pharmacokinetics of lignocaine and beta-adrenoceptor antagonists in patients with acute myocardial infarction.

Authors:  S Nattel; G Gagne; M Pineau
Journal:  Clin Pharmacokinet       Date:  1987-11       Impact factor: 6.447

8.  Regional myocardial ajmaline concentration and antiarrhythmic activity for ischaemia- and reperfusion-induced arrhythmias in rats.

Authors:  K Okumura; Y Hashimoto; M Yasuhara; R Hori
Journal:  Br J Pharmacol       Date:  1988-04       Impact factor: 8.739

Review 9.  The treatment of atrial fibrillation. An evaluation of drug therapy, electrical modalities and therapeutic considerations.

Authors:  S Nattel; T Hadjis; M Talajic
Journal:  Drugs       Date:  1994-09       Impact factor: 9.546

10.  Amiodarone Treatment in the Early Phase of Acute Myocardial Infarction Protects Against Ventricular Fibrillation in a Porcine Model.

Authors:  Stefan M Sattler; Anniek F Lubberding; Lasse Skibsbye; Reza Jabbari; Reza Wakili; Thomas Jespersen; Jacob Tfelt-Hansen
Journal:  J Cardiovasc Transl Res       Date:  2019-01-07       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.